Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Kavya Ramkumar"'
Autor:
Bingnan Zhang, Kavya Ramkumar, Robert John Cardnell, Carl Michael Gay, C. Allison Stewart, Wei-Lien Wang, Junya Fujimoto, Ignacio I. Wistuba, Lauren Averett Byers
Publikováno v:
Br J Cancer
DNA-damaging agents exploit increased genomic instability, a hallmark of cancer. Recently, inhibitors targeting the DNA damage response (DDR) pathways, such as PARP inhibitors, have also shown promising therapeutic potential. However, not all tumors
Autor:
Carl M. Gay, C. Allison Stewart, Elizabeth M. Park, Lixia Diao, Sarah M. Groves, Simon Heeke, Barzin Y. Nabet, Junya Fujimoto, Luisa M. Solis, Wei Lu, Yuanxin Xi, Robert J. Cardnell, Qi Wang, Giulia Fabbri, Kasey R. Cargill, Natalie I. Vokes, Kavya Ramkumar, Bingnan Zhang, Carminia M. Della Corte, Paul Robson, Stephen G. Swisher, Jack A. Roth, Bonnie S. Glisson, David S. Shames, Ignacio I. Wistuba, Jing Wang, Vito Quaranta, John Minna, John V. Heymach, Lauren Averett Byers
Despite molecular and clinical heterogeneity, small cell lung cancer (SCLC) is treated as a single entity with predictably poor results. Using tumor expression data and non-negative matrix factorization, we identify four SCLC subtypes defined largely
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf114567ac73384b7a47842de140eb34
http://hdl.handle.net/11591/462644
http://hdl.handle.net/11591/462644
Autor:
Kavya Ramkumar, C. Allison Stewart, Kasey R. Cargill, Carminia M. Della Corte, Qi Wang, Li Shen, Lixia Diao, Robert J. Cardnell, David H. Peng, B. Leticia Rodriguez, You-Hong Fan, John V. Heymach, Jing Wang, Carl M. Gay, Don L. Gibbons, Lauren A. Byers
Publikováno v:
Mol Cancer Res
AXL, a TAM (TYRO3, AXL, and MERTK) family receptor tyrosine kinase, is increasingly being recognized as a key determinant of resistance to targeted therapies, as well as chemotherapy and radiation in non–small cell lung cancer (NSCLC) and other can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::650c25300249ecad37f637965aa2b54a
https://europepmc.org/articles/PMC7925356/
https://europepmc.org/articles/PMC7925356/
Autor:
Carminia M. Della Corte, Liz Lauren Ajpacaja, Robert J Cardnell, Carl M Gay, Lixia Diao, Qi Wang, Kavya Ramkumar, Allison C. Stewart, Rebecca B. Kow, Hannah E Stumpf, You-Hong Fan, Jing Wang, John V Heymach, Lauren A. Byers
Publikováno v:
Molecular Cancer Therapeutics. 18:B064-B064
Background: Small cell lung cancer (SCLC) is characterized by a loss of TP53 and RB1 and by amplification of MYC in about 25% of patients. Our group and others have shown that MYC-driven SCLC cell lines are vulnerable to Aurora Kinase A (AURKA) inhib
Autor:
Carminia Maria Della Corte, Jing Wang, Robert J. Cardnell, Kavya Ramkumar, Lixia Diao, Vali Papadimitrakopoulou, Lauren Averett Byers, John V. Heymach, Don L. Gibbons
Publikováno v:
Molecular Cancer Therapeutics. 18:B024-B024
Therapeutic resistance limits effective treatment of non-small cell lung cancer (NSCLC) and a better understanding of mechanisms contributing to resistance and strategies to overcome these are urgently needed. AXL, a TAM family receptor tyrosine kina
Autor:
Jeanne A. Stuckey, Elizabeth Ziemke, Si Li, Soma Samanta, Anahita Kyani, Judith S. Sebolt-Leopold, Shuzo Tamura, Vladimir N. Yarovenko, Nouri Neamati, Kavya Ramkumar, Krishnapriya Chinnaswamy, Mats Ljungman, Hiroyuki Otake, Suhui Yang, Bikash Debnath
Publikováno v:
Nature Communications
Nature Communications, Vol 7, Iss 1, Pp 1-13 (2016)
Nature Communications, Vol 7, Iss 1, Pp 1-13 (2016)
Glutathione S-transferase omega 1 (GSTO1) is an atypical GST isoform that is overexpressed in several cancers and has been implicated in drug resistance. Currently, no small-molecule drug targeting GSTO1 is under clinical development. Here we show th
Autor:
Lauren Averett Byers, Youhong Fan, Jing Wang, John V. Heymach, Don L. Gibbons, Pan Tong, David H. Peng, Kavya Ramkumar
Publikováno v:
Cancer Research. 79:276-276
Therapeutic resistance limits effective treatment of non-small cell lung cancer (NSCLC) and a better understanding of mechanisms contributing to resistance and strategies to overcome these are urgently needed. AXL, a TAM family receptor tyrosine kina
Publikováno v:
Medicinal Research Reviews. 30:890-954
In recent years, HIV-1 integrase (IN) has become an attractive target for designing antiretroviral agents. The first IN inhibitor approved for clinical use, raltegravir, has validated the pharmacological viability of IN inhibitors and signals the adv
Autor:
Kavya Ramkumar, M. Ravi Kumar, Raveendra Dayam, Narasu Lakshmi, Kalle M. Arunasree, Jagarlapudi A. R. P. Sarma, Dharmarajan Sriram, B.V.S. Suneel Kumar, Nouri Neamati, Thimmappa H. Manjashetty, Gundla Rambabu
Publikováno v:
Current topics in medicinal chemistry. 14(17)
Fibroblast growth factor receptor 1 (FGFR1) a tyrosine kinase receptor, plays important roles in angiogenesis, embryonic development, cell proliferation, cell differentiation, and wound healing. The FGFR isoforms and their receptors (FGFRs) considere
Publikováno v:
ChemInform. 42
In recent years, HIV-1 integrase (IN) has become an attractive target for designing antiretroviral agents. The first IN inhibitor approved for clinical use, raltegravir, has validated the pharmacological viability of IN inhibitors and signals the adv